CS
SGTX

Credit Suisse’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Credit Suisse’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 4459
2022
Q2 		$0 Buy
+1
New +$13 ﹤0.01% 4527

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Credit Suisse's SGTX Position: Q3 2022 in Review

Credit Suisse sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in SGTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 33 funds tracked by Wall St. Rank hold SGTX as of Q3 2022.

  • Credit Suisse reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 1 Sigilon Therapeutics, Inc. Common Stock share in Q3 2022.
  • Credit Suisse first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Sigilon Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 33 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.